Eastern Cooperative Oncology Group

东部肿瘤合作组

• 批准号: 6780148
• 负责人: Michael Benjamin Atkins
• 金额: $ 13.27万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-12 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6780148
• 关键词: AIDS; antineoplastics; biological response modifiers; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; fluorescent in situ hybridization; gastrointestinal neoplasms; gene therapy; head /neck neoplasm; health behavior; human subject; human therapy evaluation; leukemia; lymphoma; melanoma; minimal residual disease; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; nucleic acid sequence; prognosis; reproductive system neoplasm; thorax neoplasm; tissue resource /registry; urinary tract neoplasms

DESCRIPTION (provided by applicant): Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School Institutions in the Longwood Medical area. The BIDMC faculty consists of an exceptional group of committed basic and clinical researchers. BIDMC is home to nationally recognized diseased-based centers of special expertise including those focusing on breast cancer, melanoma, renal cancer, prostate cancer and hepatic malignancies. BIDMC investigators are active participants in SPORE grants focused on Breast, Skin, Renal, Prostate and Lung Cancers. Areas of renowned scientific expertise include: vaccine and cytokine therapy, angiogenesis and signal transduction inhibition. In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes all Harvard Medical School affiliated institutions: BIDMC, Dana-Farber Cancer Institute, Brigham and Woman's Hospital, Massachusetts General Hospital, Children's Hospital Medical Center, Harvard Medical School and Harvard School of Public Health. The formation of DF/HCC will greatly enhance the ability to accrue to ECOG and CTSU trials. BIDMC has been a main ECOG Institution since 1997 and is very committed to clinical research. Over the last five years BIDMC has consistently recruited over 50 patients to therapeutic and prevention trials a year. BIDMC has successfully enrolled over 310 patients from January 1998 to December 2002. To date, in 2003, BIDMC has recruited 43 patients. In order to facilitate successful patient enrollment, BIDMC has significantly increased the number of data managers, nurses and support staff working on ECOG trials. We are committed to further our growth in laboratory and clinical research and increase our administrative participation in EOCG.

描述（由申请人提供）：贝丝以色列执事医疗中心（BIDMC）是由1996年贝丝以色列和新英格兰执事医院合并的，朗伍德医疗区的两家邻居和哈佛大学的主要医学院机构。 BIDMC教职员工由一组杰出的基本和临床研究人员组成。 BIDMC是全国认可的基于患病的特殊专业知识中心的所在地，包括专注于乳腺癌，黑色素瘤，肾癌，前列腺癌和肝恶性肿瘤的人。 BIDMC研究人员是积极参与孢子赠款的参与者，这些孢子赠款专注于乳房，皮肤，肾脏，前列腺和肺癌。 著名的科学专业知识领域包括：疫苗和细胞因子疗法，血管生成和信号转导抑制。 In 1999, the BIDMC participated in the founding of the Dana-Farber/Harvard Cancer Center (DF/HCC), which includes all Harvard Medical School affiliated institutions: BIDMC, Dana-Farber Cancer Institute, Brigham and Woman's Hospital, Massachusetts General Hospital,儿童医院医疗中心，哈佛医学院和哈佛公共卫生学院。 DF/HCC的形成将大大增强ECOG和CTSU试验的能力。 BIDMC自1997年以来一直是主要的ECOG机构，并且非常致力于临床研究。 在过去的五年中，BIDMC始终每年招募50多名患者进行治疗和预防试验。 从1998年1月到2002年12月，BIDMC已成功招募了310多名患者。迄今为止，BIDMC招募了43名患者。 为了促进成功的患者入学率，BIDMC大大增加了从事ECOG试验的数据经理，护士和支持人员的数量。 我们致力于进一步发展实验室和临床研究，并增加我们对EOCG的行政参与。